[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"company:KROS":3,"prompts:company:0001664710":22,"buybacks:0001664710:12":49,"months:0001664710:36":113,"side:events:0001664710":127,"filings:0001664710":149},{"status":4,"company":5,"choices":20,"suggestions":21},"found",{"cik":6,"name":7,"ticker":8,"exchange":9,"listings":10,"delisted":15,"coverage":16},"0001664710","Keros Therapeutics, Inc.","KROS","NASD",[11],{"ticker":8,"glr_ticker":12,"exchange":9,"type":13,"delisted_on":14},"NASD:KROS","Common Stock",null,false,{"buybacks":17},{"published":18,"published_at":19},true,"2026-11-17",[],[],{"placement":23,"items":24},"company",[25,30,34,38,44],{"id":26,"title":27,"hint":28,"kind":29,"question":27,"target":14},"asr-3nc2","How does a 3nc2 ASR look for me?","Pricer · discount, size vs. ADV","analyze",{"id":31,"title":32,"hint":33,"kind":29,"question":32,"target":14},"compare-3nc2-6nc4","Compare 3nc2 vs 6nc4","Two pricers side by side",{"id":35,"title":36,"hint":37,"kind":29,"question":36,"target":14},"backtest-2y","Backtest an ASR over 2 years","Backtest · chart",{"id":39,"title":40,"hint":41,"kind":42,"question":14,"target":43},"outstanding","What do I have outstanding?","Public · no email needed","page","buybacks#outstanding",{"id":45,"title":46,"hint":47,"kind":48,"question":14,"target":14},"convert-terms","Terms for a new convert","Coming next","soon",{"company":50,"data_as_of":51,"checked_at":52,"has_active_program":18,"authorized_total":53,"remaining_total":60,"nearest_expiration":64,"programs":72,"recent_quarters":105,"did_asr":15,"asrs":112},{"cik":6,"name":7,"ticker":8,"exchange":9},"2026-11-16","2026-11-18T03:24:08.715183Z",{"value":54,"status":55,"as_of":51,"source":56},10000000,"reported",{"accession":57,"form":58,"as_of":51,"filed_at":51,"url":59},"0001664710-26-000072","8-K","https:\u002F\u002Fwww.sec.gov\u002FArchives\u002Fedgar\u002Fdata\u002F1664710\u002F000166471026000072\u002F",{"value":61,"status":62,"as_of":51,"source":63},8350663,"estimated",{"accession":57,"form":58,"as_of":51,"filed_at":51,"url":59},{"value":65,"status":55,"as_of":66,"source":67},"2027-02-28","2026-09-30",{"accession":68,"form":69,"as_of":66,"filed_at":70,"url":71},"0001664710-26-000066","10-Q","2026-11-05","https:\u002F\u002Fwww.sec.gov\u002FArchives\u002Fedgar\u002Fdata\u002F1664710\u002F000166471026000066\u002F",[73,89],{"authorized":74,"unit":77,"authorized_as_stated":78,"price_as_of":14,"date_authorized":80,"expiration_date":82,"remaining":84,"remaining_as_stated":86,"description":88},{"value":75,"status":55,"as_of":51,"source":76},5000000,{"accession":57,"form":58,"as_of":51,"filed_at":51,"url":59},"usd",{"value":75,"status":55,"as_of":51,"source":79},{"accession":57,"form":58,"as_of":51,"filed_at":51,"url":59},{"value":51,"status":55,"as_of":51,"source":81},{"accession":57,"form":58,"as_of":51,"filed_at":51,"url":59},{"value":14,"status":83,"as_of":14,"source":14},"not_found",{"value":75,"status":62,"as_of":51,"source":85},{"accession":57,"form":58,"as_of":51,"filed_at":51,"url":59},{"value":75,"status":62,"as_of":51,"source":87},{"accession":57,"form":58,"as_of":51,"filed_at":51,"url":59},"Stock repurchase program for up to $5 million of common stock following receipt of $20 million development milestone payment from Takeda",{"authorized":90,"unit":77,"authorized_as_stated":92,"price_as_of":14,"date_authorized":94,"expiration_date":97,"remaining":99,"remaining_as_stated":102,"description":104},{"value":75,"status":55,"as_of":66,"source":91},{"accession":68,"form":69,"as_of":66,"filed_at":70,"url":71},{"value":75,"status":55,"as_of":66,"source":93},{"accession":68,"form":69,"as_of":66,"filed_at":70,"url":71},{"value":95,"status":55,"as_of":66,"source":96},"2026-09-08",{"accession":68,"form":69,"as_of":66,"filed_at":70,"url":71},{"value":65,"status":55,"as_of":66,"source":98},{"accession":68,"form":69,"as_of":66,"filed_at":70,"url":71},{"value":100,"status":55,"as_of":66,"source":101},3350663,{"accession":68,"form":69,"as_of":66,"filed_at":70,"url":71},{"value":100,"status":55,"as_of":66,"source":103},{"accession":68,"form":69,"as_of":66,"filed_at":70,"url":71},"On September 8, 2026, our board of directors authorized a stock repurchase program to repurchase up to $5.0 million of our common stock from time to time prior to February 28, 2027 (the “September 2026 Repurchase Program”).",[106],{"period_start":107,"period_end":66,"shares":108,"avg_price":109,"value_usd":110,"source":111},"2026-07-01",146342,11.27,1649274.3399999999,{"accession":68,"form":69,"as_of":66,"filed_at":70,"url":71},[],{"company":114,"data_as_of":51,"items":115},{"cik":6,"name":7,"ticker":8,"exchange":9},[116,120,124],{"period_start":107,"period_end":117,"open_market_shares":118,"total_shares":118,"program_shares":118,"asr_shares":14,"avg_price":118,"value_usd":118,"remaining":118,"remaining_unit":77,"source":119},"2026-07-31",0,{"accession":68,"form":69,"as_of":66,"filed_at":70,"url":71},{"period_start":121,"period_end":122,"open_market_shares":118,"total_shares":118,"program_shares":118,"asr_shares":14,"avg_price":118,"value_usd":118,"remaining":118,"remaining_unit":77,"source":123},"2026-08-01","2026-08-31",{"accession":68,"form":69,"as_of":66,"filed_at":70,"url":71},{"period_start":125,"period_end":66,"open_market_shares":108,"total_shares":108,"program_shares":108,"asr_shares":14,"avg_price":109,"value_usd":110,"remaining":100,"remaining_unit":77,"source":126},"2026-09-01",{"accession":68,"form":69,"as_of":66,"filed_at":70,"url":71},{"view":128,"sort":129,"total":130,"generated_at":131,"items":132,"next_cursor":14},"all","newest",3,"2026-11-20T08:32:20.851996Z",[133,139,145],{"id":134,"type":135,"event_date":51,"company":136,"amount_usd":75,"amount_estimated":15,"shares":14,"headline":137,"source":138},"ae13bd01-0703-514f-92fd-6aca19174707","authorization_new",{"cik":6,"name":7,"ticker":8,"exchange":9},"Keros Therapeutics, Inc. authorizes $5m share repurchase program",{"accession":57,"form":58,"as_of":51,"filed_at":51,"url":59},{"id":140,"type":141,"event_date":66,"company":142,"amount_usd":110,"amount_estimated":15,"shares":108,"headline":143,"source":144},"1fc0d656-d15e-5cd6-bba2-e8517573fed9","quarterly_repurchase",{"cik":6,"name":7,"ticker":8,"exchange":9},"Keros Therapeutics, Inc. repurchased 146,342 shares ($2m) in the quarter to Sep 30, 2026",{"accession":68,"form":69,"as_of":66,"filed_at":70,"url":71},{"id":146,"type":135,"event_date":95,"company":147,"amount_usd":75,"amount_estimated":15,"shares":14,"headline":137,"source":148},"e0e4e2db-85b5-57f8-aa2e-d19e740dd435",{"cik":6,"name":7,"ticker":8,"exchange":9},{"accession":68,"form":69,"as_of":66,"filed_at":70,"url":71},{"company":150,"items":151,"edgar_url":161},{"cik":6,"name":7,"ticker":8,"exchange":9},[152,157],{"accession":57,"form":58,"filed_at":153,"period_end":51,"url":59,"used_for":154},"2026-11-16T16:04:41Z",[155,156],"programs","remaining_total",{"accession":68,"form":69,"filed_at":158,"period_end":66,"url":71,"used_for":159},"2026-11-05T16:04:02Z",[155,160,156],"recent_quarters","https:\u002F\u002Fwww.sec.gov\u002Fcgi-bin\u002Fbrowse-edgar?action=getcompany&CIK=0001664710"]